Findings

What do systematic reviews say?

186 questions · 190 findings · 17 reviews · Haematology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 47 · 24.7%GRADE not reported 21 · 11.1%Very low 26 · 13.7%Low 47 · 24.7%Moderate 37 · 19.5%High 12 · 6.3%

Thrombopoietin mimetics vs placebo or usual care

Quality of life ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation

The review found no eligible studies for this question.

1 finding from 1 review

Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Number of participants with at least 1 bleeding episode · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation

It is very uncertain whether the intervention changes number of participants with at least 1 bleeding episode (very low certainty).

1 finding from 1 review

Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… 2016 · Cochrane Headline outcomes only
OR 16 [1.32, 194.62]
1 study · 18 participants
Very low

Intervention not reported

All cause mortality · cancer patients receiving myelotoxic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Incidence of febrile neutropenia · cancer patients receiving myelotoxic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Incidence of severe infections (Grade III or IV) · cancer patients receiving myelotoxic chemotherapy

The intervention showed no clear difference in incidence of severe infections (Grade III or IV) (low certainty).

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
RR 1.55 [0.86, 2.8]
1 study · 115 participants
Low

Intervention not reported

Adverse events Toxic deaths · cancer patients receiving myelotoxic chemotherapy

The intervention showed no clear difference in adverse events Toxic deaths (low certainty).

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
RR 1.32 [0.3, 5.69]
1 study · 115 participants
Low

Intervention not reported

Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low

Intervention not reported

Quality of life · cancer patients receiving myelotoxic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Incidence of febrile neutropenia · cancer patients receiving myelotoxic chemotherapy

It is very uncertain whether the intervention changes incidence of febrile neutropenia (very low certainty).

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
RR 1.22 [0.53, 2.84]
1 study · 40 participants
Very low

Intervention not reported

Incidence of severe infections · cancer patients receiving myelotoxic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Adverse events · cancer patients receiving myelotoxic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All cause mortality · cancer patients receiving myelotoxic chemotherapy

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 115 participants
Low

Intervention not reported

Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Quality of life · cancer patients receiving myelotoxic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion

Number of participants with at least 1 bleeding episode · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation

1 finding from 1 review

A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with… 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 801 participants
GRADE not reported

Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion

Bleeding: Number of days on which a significant bleeding event occurred3 · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation

1 finding from 1 review

A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with… 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 599 participants
Moderate

Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion

Number of participants with severe or life‐threatening bleeding · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation

Therapeutic or non‐prophylactic platelet transfusion showed no clear difference in number of participants with severe or life‐threatening bleeding up… compared with prophylactic platelet transfusion (low certainty).

1 finding from 1 review

A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with… 2015 · Cochrane Headline outcomes only
RR 4.91 [0.86, 28.12]
2 studies · 801 participants
Low

Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion

Time to first bleeding episode (days) · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation

1 finding from 1 review

A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with… 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 801 participants
GRADE not reported

Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion

Mortality from all causes up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation

1 finding from 1 review

A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with… 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 629 participants
GRADE not reported

Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion

Number of platelet transfusions per participant up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation

1 finding from 1 review

A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with… 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 801 participants
Moderate